Published in Eur J Nucl Med Mol Imaging on November 12, 2016
FDG-PET imaging to detect and characterize infectious disorders; an unavoidable path for the foreseeable future. Eur J Nucl Med Mol Imaging (2017) 0.75
Infection in solid-organ transplant recipients. N Engl J Med (2007) 5.47
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature (1999) 3.93
Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol (2006) 3.00
Cancer Mortality Among Recipients of Solid-Organ Transplantation in Ontario, Canada. JAMA Oncol (2016) 2.14
Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation (2004) 1.68
The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer (2005) 1.64
Fever of unknown origin: the role of 18F-FDG PET/CT. J Nucl Med (2008) 1.52
The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging (2004) 1.47
Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med (2014) 1.47
Immunosuppressive strategies in transplantation. Lancet (1999) 1.38
When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Nucl Med Mol Imaging (2013) 1.37
EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med (2013) 1.37
18F-FDG PET/CT for detection of metastatic infection in gram-positive bacteremia. J Nucl Med (2010) 1.27
Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl Int (2007) 1.14
FDG PET/CT in infection and inflammation--current and emerging clinical applications. Clin Radiol (2015) 1.14
F-18 FDG PET/CT in the diagnosis of fever of unknown origin. Clin Nucl Med (2009) 1.12
Physiological uptake in FDG PET simulating disease. Biomed Imaging Interv J (2006) 1.10
Cost-effectiveness of routine (18)F-FDG PET/CT in high-risk patients with gram-positive bacteremia. J Nucl Med (2011) 1.09
Positron emission tomography scanning in the setting of post-transplant lymphoproliferative disorders. Clin Transplant (2010) 1.09
Fever of unknown origin. Semin Nucl Med (2009) 1.06
PET imaging of inflammation biomarkers. Theranostics (2013) 1.04
Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica (2011) 0.96
Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma. Eur J Nucl Med Mol Imaging (2007) 0.94
Potential of noninvasive serial assessment of acute renal allograft rejection by 18F-FDG PET to monitor treatment efficiency. J Nucl Med (2010) 0.94
Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of ¹⁸F-FDG PET/CT. PLoS One (2013) 0.91
Immunosuppression and risk of cervical cancer. Expert Rev Anticancer Ther (2013) 0.89
The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection. Am J Transplant (2013) 0.89
Atypical mycobacteriosis caused by Mycobacterium haemophilum in an immunocompromised patient: diagnosis by (18)F-FDG PET/CT. Clin Nucl Med (2013) 0.88
New concepts and best practices for management of pre- and post-transplantation cancer. Transplant Rev (Orlando) (2012) 0.88
De novo malignancies in renal transplant recipients: experience at a single center with 1882 transplant patients over 39 yr. Clin Transplant (2012) 0.87
Increased T cell glucose uptake reflects acute rejection in lung grafts. Am J Transplant (2013) 0.86
Immunodeficiency, immunosuppression, and susceptibility to neoplasms. J Natl Cancer Inst Monogr (2001) 0.85
Diagnostic performance of 18F-FDG-PET/CT in vascular graft infections. Eur J Vasc Endovasc Surg (2015) 0.85
Clinical usefulness of 18F-FDG PET in nasopharyngeal carcinoma patients with questionable MRI findings for recurrence. J Nucl Med (2004) 0.84
Modest utility of quantitative measures in (18)F-fluorodeoxyglucose positron emission tomography scanning for the diagnosis of aortic prosthetic graft infection. J Vasc Surg (2014) 0.83
Use of [18F]FDG Positron Emission Tomography to Monitor the Development of Cardiac Allograft Rejection. Transplantation (2015) 0.82
Early restaging whole-body (18)F-FDG PET during induction chemotherapy predicts clinical outcome in patients with locoregionally advanced nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging (2005) 0.82
Comparative evaluation of SUV, tumor-to-blood standard uptake ratio (SUR), and dual time point measurements for assessment of the metabolic uptake rate in FDG PET. EJNMMI Res (2016) 0.81
Long-term survival after allogeneic haematopoietic cell transplantation for AML in remission: single-centre results after TBI-based myeloablative and non-myeloablative conditioning. Bone Marrow Transplant (2013) 0.80
Contribution of 18fluoro-deoxyglucose PET/CT for the diagnosis of infectious diseases. Med Mal Infect (2014) 0.78
Clinical value of pre-and postoperative 18F-FDG PET/CT in patients undergoing liver transplantation for hepatocellular carcinoma. Nan Fang Yi Ke Da Xue Xue Bao (2006) 0.78
SPECT- and PET-based approaches for noninvasive diagnosis of acute renal allograft rejection. Biomed Res Int (2014) 0.78
Potential performance of dual-time-point 18F-FDG PET/CT compared with single-time-point imaging for differential diagnosis of metastatic lymph nodes: a meta-analysis. Nucl Med Commun (2014) 0.78
Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management. Ann Thorac Surg (2014) 0.78
False-positive rate of positron emission tomography/computed tomography for presumed solitary metastatic adrenal disease in patients with known malignancy. Ann Surg Oncol (2014) 0.77
Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results. Eur J Nucl Med Mol Imaging (2016) 0.77